Firmonertinib vs placebo for early-stage lung cancer with rare EGFR mutations
Treatments studied
Part of Cancer clinical trials.
This trial tests if Firmonertinib, a targeted pill, can prevent lung cancer from returning after surgery in people with non-small cell lung cancer that has certain uncommon EGFR gene changes. If you have had complete tumor removal and have one of these specific mutations, this study may help you stay cancer-free longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old (or 20 in Japan/Taiwan).
- You have a type of lung cancer called non-small cell lung cancer that is not mostly squamous cells.
- You have had full surgical removal of your lung tumor (no cancer left behind) and lymph node dissection.
- Your cancer stage after surgery is IB, II, IIIA, or IIIB (only T3N2M0 for IIIB).
- Your tumor has an uncommon EGFR mutation (exon 20 insertion, PACC, or classical-like) found by a special test.
- You have not had any prior cancer treatment except standard platinum-based chemotherapy after surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted cancer drug called firmonertinib for early-stage lung adenocarcinoma that can be surgically removed. The drug targets a specific genetic mutation (EGFR) in the cancer cells and is given before and after surgery to help prevent the cancer from returning.
This trial tests combining a targeted pill (firmonertinib) with medication injected into the fluid around the spine for people with a specific type of lung cancer that has spread to the lining of the brain. It may offer a new option if you have already tried other EGFR drugs and are still having progression.
This trial compares a new targeted therapy pill (firmanertinib) to standard chemotherapy in people with advanced non-small cell lung cancer whose tumors have a specific EGFR mutation (PACC or L861Q). If you haven't had treatment for advanced disease and your cancer matches these mutations, this study may offer a more convenient oral option.
This Phase 2 trial studies whether furmonertinib can lower the risk of lung cancer coming back after surgery in certain early-stage lung cancers. You must have EGFR mutations and specific higher-risk features seen on the tumor’s pathology.
This trial tests whether combining a targeted therapy (Firmonertinib) with a drug that blocks blood vessel growth (bevacizumab/Avastin) before surgery can shrink tumors in people with a specific type of lung cancer (EGFR mutation-positive, stages II–IIIB). The goal is to increase the chance of successful surgery.
This trial tests if a targeted therapy pill (befotertinib) can lower the chance of cancer coming back after surgery for non-small cell lung cancer that has a specific EGFR mutation. You may be eligible if your tumor was completely removed and you have stage IB to IIIB disease.
Hear when a new Adjuvant Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.